ARENSIA NEWSLETTER - 1st HALF OF 2019

HOME NEWS ARENSIA NEWSLETTER - 1ST HALF OF 2019
ARENSIA NEWSLETTER - 1st HALF OF 2019
Dear Colleagues, Partners and Collaborators,

It has been a tremendous 1st half of 2019 with some really exciting developments at ARENSIA.  
Our continued dedication to complex early phase Ib/IIa studies has amounted to over 50 trials across our units since the beginning of 2019. Below are some of our most recent study achievements:
We have also made some considerable corporate milestones during this year:

ARENSIA’s dedication in pioneering innovating approaches in performing safe, fast, quality complex early phase patient trials continue to help our sponsors achieve their research targets and importantly change patient’s lives daily.

Recent Recruitment Metrics from a range of Therapeutic Areas:

INDICATION

STUDY PHASE/DESIGN

RECRUITMENT ACHIEVEMENTS

LOCATION

Pulmonary Arterial Hypertension
(moderate to severe)

Phase I - ambulatory visits

11 patients in 8 weeks

1 unit: Moldova

Hepatic impairment (severe)

Phase I - 6 days hospitalization

5 patients in 32 weeks

1 unit: Romania

Metastatic Gastric Cancer
(HER2 overexpression)

Phase Ib - ambulatory visits

6 patients in 14 weeks

2 units: Moldova & Georgia

Chronic HBV
HBV-DNA Positive

Phase I - 4 days hospitalization

6 patients in 1 week

1 unit: Moldova

Atopic Dermatitis
(moderate to severe)

Phase I - ambulatory visits

14 subjects in 22 weeks

1 unit: Ukraine

Ulcerative Colitis (moderate to severe)

Phase I - 9 days hospitalization

11 patients in 10 weeks

2 units: Moldova & Georgia

HIV

Phase I - 2 days hospitalization

17 patients in 18 weeks

1 unit: Romania

09.09.2019
CONTACT US